Drugs / 12-O-tetradecanoylphorbol-13-acetate
12-O-tetradecanoylphorbol-13-acetate
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00004058 | Dec 1998 → Nov 2004 | leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloproliferative neoplasm +2 | University of Medicine and Dentistry of New Jersey | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01795924 | Jan 2013 → Sep 2014 | acute myeloid leukemia, myelodysplastic syndrome | Biosuccess Biotech Co., Ltd. | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01009931 | Mar → Oct 2011 | leukemia | Rutgers, The State University of New Jersey | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 12-O-tetradecanoylphorbol-13-acetate | “Phase I Study of 12-O-tetradecanoylphorbol-13-acetate (TPA) in Patients With Refractory Hematologic Malignancies/Bone Marrow Disorders” NCT00004058 ↗ |
| Known as | PD-616 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01795924 ↗ |
| Known as | tetradecanoylphorbol acetate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004058 ↗ |
| Known as | TPA | “Phase I Study of 12-O-tetradecanoylphorbol-13-acetate (TPA) in Patients With Refractory Hematologic Malignancies/Bone Marrow Disorders” NCT00004058 ↗ |
| Route | Intravenous | “Patients receive 12-O-tetradecanoylphorbol-13-acetate (TPA) IV over 1 hour” NCT00004058 ↗ |